TCTR20211203004已完成1 期
A Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Thai Volunteers under Fed Conditions
ovugen Pharma (Malaysia) Sdn. Bhd0 个研究点目标入组 24 人开始时间: 2021年12月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
Rivaroxaban Film-Coated Tablets 20 mg is bioequivalent to Xarelto 20 mg
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Thai male/female must be 18-55 years of age, body weight >50.0 kg with body mass index (BMI) = 18.0-30.0 kg/m2, inclusive.
- •2.Must be in good health as determined by medical history, vital signs (blood pressure (systolic blood pressure not lower than 90 or not over 129 mmHg, diastolic blood pressure not lower than 60 or not over 79 mmHg), body temperature, pulse rate, respiratory rate) and physical examination or showing no clinically significant abnormalities in the opinion of principal investigator or designated physicians
- •3.Screening electrocardiogram (ECG) without clinically significant abnormalities
- •4.Screening visit laboratory values of blood test including hematology (complete blood count (CBC) with differential), fasting blood sugar (FBS), blood urea nitrogen (BUN), creatinine (Cr), and liver function test (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin and alkaline phosphatase (ALP)) must be within the normal range or showing no clinically significant abnormalities in the opinion of principal investigator or designated physicians.
- •5.PT and aPTT should be within normal range or showing no clinically significant abnormalities in the opinion of clinical investigator.
- •6.Thai cardiovascular (CV) risk score must be according to 2016 Royal College of Physicians of Thailand (RCPT) Clinical Practice Guideline on Pharmacologic Therapy of Dyslipidemia for Atherosclerotic Cardiovascular Disease Prevention or showing no clinically significant abnormalities in the opinion of principal investigator or designated physicians. Screening visit laboratory values of lipid profile (total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) will be obtained for low-density lipoprotein cholesterol (LDL-C) and Thai CV risk score calculation.
- •7.Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of principal investigator or designated physicians.
- •8.Must have serum hepatitis B surface antigen (HBsAg) seronegative
排除标准
- •1.Known hypersensitivity to rivaroxaban, any other similar class of drugs or its components
- •2.Past medical history of renal and hepatic insufficiency
- •3.Subject has a history of any illness that, in the opinion of principal investigator or designated physicians, might confound the result of the study or pose an additional risk in administering study drug to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal (especially gastrointestinal ulcer), central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements.
- •4.Have a history of significant hemorrhage within 6 months
- •5.Known of coagulation disorders (this may include but is not limited to hemophilia) or sensitive to common cause of bleeding
- •6.Have condition associated with an increase risk of bleeding. This may include but is not limited to: periodontitis, hemorrhoids acute gastroenteritis and acute peptic ulcer.
研究者
相似试验
招募中
不适用
Bioequivalence study of Rivaroxaban 20 mg tabletBioequivalence study of Rivaroxaban 20 mg tablet (Tehran Darou) versus Xalerto® 20 mg (Bayer) Tablet after single oral dosing in healthy volunteers.IRCT20220111053692N4tehran darou Pharmaceutical Company24
尚未招募
Unknown
Bioequivalence study of Rivaroxaban 20mg tabletIRCT20200623047902N28Darou Darman Arang company24
已完成
1 期
Bioequivalence Study of Rivaroxaban 20 mg Film-coated TabletsHealthyNCT06558045Dexa Medica Group26
已完成
1 期
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsEmbolism, Atrial Fibrillation and Venous ThrombosisNCT02537405Bayer40
已完成
1 期
Bioequivalence Study of Rivaroxaban 10 mg Film-coated TabletsHealthyNCT06558058Dexa Medica Group28